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Abstract
Integration of HIV DNA into host chromosome requires a 39-processing (39-P) and a strand transfer (ST) reactions catalyzed
by virus integrase (IN). Raltegravir (RAL), commonly used in AIDS therapy, belongs to the family of IN ST inhibitors (INSTIs)
acting on IN-viral DNA complexes (intasomes). However, studies show that RAL fails to bind IN alone, but nothing has been
reported on the behaviour of RAL toward free viral DNA. Here, we assessed whether free viral DNA could be a primary target
for RAL, assuming that the DNA molecule is a receptor for a huge number of pharmacological agents. Optical spectroscopy,
molecular dynamics and free energy calculations, showed that RAL is a tight binder of both processed and unprocessed LTR
(long terminal repeat) ends. Complex formation involved mainly van der Waals forces and was enthalpy driven. Dissociation
constants (Kds) revealed that RAL affinity for unbound LTRs was stronger than for bound LTRs. Moreover, Kd value for
binding of RAL to LTRs and IC50 value (half concentration for inhibition) were in same range, suggesting that RAL binding to
DNA and ST inhibition are correlated events. Accommodation of RAL into terminal base-pairs of unprocessed LTR is
facilitated by an extensive end fraying that lowers the RAL binding energy barrier. The RAL binding entails a weak damping
of fraying and correlatively of 39-P inhibition. Noteworthy, present calculated RAL structures bound to free viral DNA
resemble those found in RAL-intasome crystals, especially concerning the contacts between the fluorobenzyl group and the
conserved 59C
4pA
339 step. We propose that RAL inhibits IN, in binding first unprocessed DNA. Similarly to anticancer drug
poisons acting on topoisomerases, its interaction with DNA does not alter the cut, but blocks the subsequent joining
reaction. We also speculate that INSTIs having viral DNA rather IN as main target could induce less resistance.
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Introduction
Integration of the HIV-1 DNA into the host chromosome leads
to the viral infection at the origin of the AIDS pandemic.
Integration is catalysed by the retroviral enzyme integrase (IN) [1–
4]. The whole integration involves the 39-processing (39-P) and the
strand transfer (ST), which occur in the cytoplasm and in the
nucleus, respectively. The integration is finalized by the cell
enzymes which cleave the viral DNA 59-overhang and fill the
room left between the viral and cellular DNA [3–5]. A huge effort
from both the public research and the pharmaceutical industry
was made during the last decade to discover IN inhibitors. Only
those acting on the ST step have emerged as interesting
antiretroviral drugs [5–7]. Thus, Merck and Co has recently
developed the raltegravir (RAL, MK-0518), a potent INSTI (IN
ST Inhibitor) that derives from DKAs (Diketo Acids) and which is
now widely used in AIDS therapy [8,9]. However, RAL induces
mutations located mainly into the loop 140 (Y143H/R/C,
Q148H/R/K and G140S-Q148H) and the a4 helix (N155H)
[10–12], entailing significant clinical resistance [11]. Positions of
these mutations in the protein are consistent with the determining
role hold by the a4 helix (residues 150 to 166) [13,14] and the loop
140 (residues 140 to 149) [11,15] of the catalytic core domain
(CCD) in the IN activity and also as sites of inhibitors [15–18].
The crystal structures recently resolved by Hare et al., 2010
confirm the coordination of two Mg
2+ to the three coplanar
oxygen or nitrogen atoms of the metal binding motif, while the
halogenated aromatic ring penetrates more or less deeply into the
space made available by the opening of the conserved 59C
4pA
339
step at the end of the processed strand. The oxadiazole moiety of
the RAL molecule further interacts through stacking interactions
with the Tyr 143 phenolic group. However, this ‘‘p-p’’ stacking
does not appear indispensable for the inhibitory activity of INSTIs
as it can be replaced by other interactions with the loop 140 amino
acid residues, as shown by the oxadiazole-lacking compounds ie
EVG (elvitegravir) [15,19,20] and the so-called new generation of
INSTIs such as MK-0536 [18,21], MK-2048 [18,22] and DTG
(dolutegravir) [23,24]. These compounds not only are fully active
against WT-IN but they also remain effective against the RAL-
resistant Y143R mutant of IN [20]. All display intermolecular
contacts (‘‘p-p’’stacking) between their halogenated aromatic ring
and the cytosine base of the conserved 59C
4pA
339step. The
subsequent spatial displacement of the adjacent 39-adenine (A
3)
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considered as the main event promoting the inhibition of
integration [15].
Actually, it is the large number of interactions occurring
between INSTIs and the viral DNA, but also the inability of RAL
to bind tightly to IN taken alone [25,26], which motivated us to
examine whether the LTR ends could be the primary targets of
the drugs. To this end we used RAL and several oligonucleotides
mimicking or deriving from the U5 LTR extremity of viral DNA
(Fig. 1). Analysis of the drug-DNA complexes was performed by
UV-absorbance [27], circular dichroism (CD) [27], fluorescence
[13], molecular dynamics simulations (GROMACS 4.5.3/Am-
ber99SB-ILDN) [28,29] and free energy calculations using the
Molecular Mechanics-Poisson Boltzmann Surface Area method
(MMPBSA) [30–33]. Results indicate that one molecule of RAL
binds tightly to 39-processed LTR (Kd<6 nM) and more weakly
to unprocessed LTR (Kd<20 nM). Binding of RAL to processed
LTR requires several key nucleotides including the 59A
21C
2239
overhang, known for its strong implication in the binding and
activity of IN [34]. The binding of RAL to this small dinucleotide
strand in unprocessed LTR is facilitated by a major fraying in
terminal base pairs that lowers the energy barrier for drug
insertion [35,36]. The insertion of RAL into the terminal base
pairs, affects slightly their fraying and similarly the 39-P reaction,
the latter reaction being closely correlated to the motions at the
LTR ends [35]. After the deletion of the 59G
2T
139 dinucleotide,
RAL blocks the ST reaction in adopting a new position at the
LTR end more conducive to binding with the two divalent cations
and the cytosine C
4 of the conserved malleable C
4pA
3 step
[15,17,18]. Remarkably, in our two modeled RAL-LTR32
structures, the adenine A
3 nucleotide that bears the essential
39OH group has conformations similar the ones found in the
crystal structures of the RAL-intasome complexes (PDB codes:
3L2T [15] and 3OYA [18]). All together, present results bring
greater clarity on the inhibitory mechanism of INSTIs, especially
in showing that the drugs may bind specifically to both the
unprocessed and processed LTR ends. The binding of RAL to
unprocessed LTR does not or little impair the 39-P reaction
because the end fraying required for the cleavage of the
phosphodiester backbone by IN is only weakly altered by RAL
[37]. The 39-P reaction produces a change of the complex
conformation, responsible for the blocking of the joining reaction
[38,39]. We also propose that anti-AIDS drugs having an
increased number of interactions with the substrate viral DNA,
at detriment of the protein active site, could induce less resistance
mutations.
Materials and Methods
Oligonucleotides and RAL
The oligonucleotides LTR34, LTR32, LTR32-I and LTR30
(Fig. 1 A) were purchased from Eurogentec (Belgium). They were
designed to adopt a monomolecular hairpin structure that remains
stable at the low concentrations used in fluorescence and CD
experiments (10
29 to 10
25 M). LTR34 reproduces the unpro-
cessed version of the U5 LTR end, LTR32 is the 39-processed
version obtained by deletion of G
2T
139 and LTR32-I (LTR32-
inverted) is obtained by deletion of C
22A
2159; blunt-ended
LTR30 is obtained by deletion of both G
2T
139 and C
22A
2159.
The thymine at the centre of the three thymine loop bears the
fluorescein reporter for fluorescence studies. Unlabeled oligonu-
cleotides were also prepared for UV-absorbance and CD
measurements. RAL (Fig. 1 B) was purchased from CacheSyn
while MK-2048 (Fig. 1 C) is given as an example of an INSTI of
the new generation. PFV LTR sequences used in calculations are
indicated in Fig. 1D.
UV-absorbance measurements
UV-spectrometry experiments were recorded by using an
Uvikon spectrophotometer model 941 (Kontron Instruments).
DNA and RAL samples were dissolved in phosphate buffer (Na/
Na2 phosphate, 10 mM, pH 6, I=0.05) in the presence of 5 mM
MgCl2. Titrations were performed using the DNA as the titrant in
10 mm and 2 mm path length quartz cells and scanning the
spectrum after each aliquot addition. The RAL concentration was
generally maintained at 20 mM and that of DNAs was varied from
1t o2 0mM. Difference spectra between 200 nm and 380 nm were
obtained by subtraction of DNA spectra from the DNA-RAL
complex spectra, after subtraction of the buffer contribution.
CD measurements
CD spectra were recorded on a Jobin-Yvon CD6 dichrograph.
Measurements were calibrated with (+)-10-camphorsulfonic acid.
Samples were dissolved in phosphate buffer. The concentration of
oligonucleotides was 10 mM while that of the titrant was varied
from 10 mMt o8 0mM. Samples were placed in thermally jacketed
cuvettes with 1–5 mm path lengths. Spectra, recorded with 1-nm
steps and corrected for the base line, were averaged over 10 scans.
Before spectral recording, samples were incubated 10 min at the
chosen temperature to allow the solutions to reach their
equilibrium state. Spectra of DNAs and complexes of RAL-
DNA were presented as CD per residue, De (M
21.cm
21), as a
function of wavelength, l (nm), between 200 and 330 nm. As RAL
lacks chirality it does not directly contribute to the spectrum. Yet,
RAL bears several chromophores which once placed in an
asymmetric environment, i.e. in the vicinity of a deoxyribose ring,
can acquire chirality and generate a signal in the absorption
region.
Fluorescence measurements
These included both fluorescence intensity and anisotropy
titration studies. Measurements were carried on a Jobin-Yvon
Fluoromax II instrument. In fluorescence intensity titrations, RAL
was maintained at a constant concentration while the DNA was
used as the titrant. For RAL the wavelengths for maximum
excitation and emission were l=313 nm and l=413 nm,
respectively. For fluorescence anisotropy (A=(III2I))/(III+2I)))
the parallel (III) and perpendicular (I)) emission components were
measured in L-format. The denominator of A was simply the total
light that would be observed if no polarizers were used. With
fluorescein as fluorophore grafted on DNA, the excitation from the
xenon lamp (150-watt ozone-free) was performed at 488 nm with
a 4-nm slit width. The emission was recorded at 516 nm with a 5-
nm slit width in the case of LTR34, at 515 nm with a 4-nm slit
width in cases of LTR32 and LTR32-I and at 514 nm with a 4-
nm slit width in the case of LTR30. The fluorescein-labeled
oligonucleotides were diluted to the desired concentration in
800 ml of phosphate buffer at the selected temperature (generally
5uC). Samples were placed in thermally jacketed 1-cm60.5-cm
quartz cuvettes, and measurements, at least 10 data points for each
titration point, were recorded with an integration time of 1 s. For
each fluorescence anisotropy measurement, the parallel (III) and
the perpendicular (I)) intensities of the background solution (i.e.
buffer and RAL contributions) were subtracted from the sample
value. The validity of fluorescence anisotropy measurements was
controlled in measuring the total fluorescence intensity in parallel
to fluorescence anisotropy. Variations of fluorescence intensity
during these experiments were very weak, so we considered that
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PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e40223the anisotropy signal contained the desired information on the
complex formation. Kds (equilibrium dissociation constants) were
calculated by fitting the sigmoidal curves, using GraphPad Prism 5
applying either the linear regression or non-linear regression
(curve fit) ‘‘Least Squares’’ procedure. Binding stoichiometries
were determined using the Bujalowsky and Lohman procedure
[40]. The reverse experiment consisting in the analysis of the
oligonucleotide binding to the drug was also carried out.
Molecular dynamics simulations of viral DNA-RAL
complexes
Molecular dynamics (MD) simulations were performed using
the GROMACS software (version 4.5.3) [28] with the Am-
ber99SB-ILDN force field [29]. RAL parameters were constructed
using the ACPYPE (AnteChamber PYthon Parser interfacE)
[41,42], the General Amber Force Field (GAFF) [41] and the
restrained electrostatic potential (RESP) charges. RESP charges
were calculated using the Antechamber program [42] using the
ESP charges calculated at Hartree-Fock [43] 6–31G* level [44]
using G03(Gaussian03, Revision C.02). Simulations on RAL-DNA
complexes were carried out on both processed and unprocessed
PFV DNAs (i.e. LTR32 and LTR34) with a single Mg
2+ ion.
Initial coordinates of the LTR32-RAL complex were extracted
from the 3OYA [18] PDB structure, after IN removal. Unpro-
cessed DNA, LTR34 of PFV (Fig. 1D), was constructed by
addition of the 59AT dinucleotide (corresponding to 59G
2T
139 in
HIV) at the 39-end of the processed strand, using the VMD
program [45]. Complexes were slightly relaxed using 50 steps of
Figure 1. Molecules used in this study. (A) The oligonucleotides are designed to adopt a hairpin structure, folded around a three thymine loop
whose central thymine bears the fluorescein reporter. LTR34: unprocessed U5-LTR end with a 17 base pair stem. The numbering of the four last base
pairs (+1t o+4 and 21t o24) starts from the ultimate 39nucleotide on the upper (+) strand and from the ultimate 59 nucleotide on the lower (2)
strand; LTR32, processed U5-LTR, with 59A
21C
2239 as overhang on the (2) strand; LTR32-I, inversed LTR32, with 59G
2T
139 as overhang in the (+)
strand; and LTR30, doubly deleted LTR34 (blunt-ended DNA). (B) Chemical structure of the here studied RAL (MK-0518). (C) Chemical structure of MK-
2048. This compound is given as an example of INSTI of second generation, inducing less resistance mutations in IN. (D) PFV LTR sequences used in
calculations. The numbering of the four last base pairs (+1t o+4 and 21t o24) is the same as in (A).
doi:10.1371/journal.pone.0040223.g001
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immersed in an explicit water box of TIP3P model [46] which
extended at least 16 A ˚ away in each direction from any DNA or
RAL atom. The systems include 14993 water molecules and
35 Na ions in the case of LTR34 (46274 atoms) and 13474 water
molecules and 33 Na ions in the case of LTR32 (41651 atoms).
Sodium ions were added to neutralize the system as needed for
the Particle Mesh Ewald (PME) [47] calculation of the long-range
electrostatic interactions, while cut-off of 10 A ˚ was used for van
der Waals (VDW) and short-range electrostatic interactions. The
system was exposed to 500 step of steepest descent minimization to
remove the bad contacts with the solvent. All bonds involving
hydrogen atoms were constrained by LINCS algorithm [48].
Equilibration of the solvent and ions around the complexes with
position constraints of the heavy atoms, were performed for two
nanoseconds in the constant Number of particles, Volume, and
Temperature (NVT) ensemble and in Constant Number of
particles, Pressure and Temperature (NPT) thermodynamic
ensemble respectively. NVT simulations were carried out using
the velocity rescaling thermostat (V-rescale) [49] and the NPT
using Parrinello-Rahman barostat [50] MD production simula-
tions were performed for a total of 400 ns duration in the NPT
ensemble. Moreover, we also performed a calculation of the
distance (nm) evolution between the center of mass of RAL and
terminal bases (59A and 39T) of the PFV LTR34, in the calculation
course from t=0 ns to 100 ns.
Binding free energy calculations
RAL binding free energies were estimated using the end point
Molecular Mechanics Poisson-Boltzmann Surface Area
(MMPBSA) method [30–33,51]. The total free energy (G) in
MMPBSA analysis for a given species (complex, receptor, and
ligand) was determined using Eq. (1); the overall change in free
energy for complex formation (DGbind) for a non-covalent binding
event was calculated according to Eq. (2).
G~GpolarzGnonpolarzEMM{TS ð1Þ
DGbind~DH{TDS~Gcomp{(GreczGlig) ð2Þ
The polar solvation energies (Gpolar) were computed in continuum
solvent using Poisson-Boltzmann (PB) and ionic force of 0.05 as
used in the experiments. The non-polar terms (Gnonpolar+cSA-
SA+b) were estimated using solvent accessible surface areas (SASA
in A ˚ [29]) with typical values for c=0.00542 kcal/mol A ˚ 2 [29]
and b=0.92 kcal/mol. The EMM term represented the sum of the
electrostatic (Coulombic), VDW (Lennard-Jones), and internal
energies (bonds, angles, and dihedrals). The remaining term
represented temperature (T) and solute entropy (S), which can be
estimated from normal-mode analysis of energy-minimized
structures or quasi-harmonic (QH) modes over stabilized region
of MD trajectory. 500 snapshots were selected from the last 5 ns,
by keeping the snapshots every 5 ps. The entropy contributions
were estimated by QH mode using 5000 frames from the last 5 ns.
The free energy analysis was carried out using MMPBSA.py script
from Amber11 program.
Results and Discussion
DNA is a target for a wide diversity of ligands. Due to the
complexity and variety of DNA structures, the binding modes of
these ligands, including anticancer agents, are them also complex
and varied (intercalation, groove binding, insertion in breaks…)
[27,38,39,52–54]. Often, a same molecule (for instance ellipticine)
can act as both an intercalator and a groove binder [27].
Moreover, anticancer agents such as camptothecin and deriva-
tives, poisons of topoisomerase I, operate through insertion into a
break of the DNA double helix created by the enzyme in one DNA
strand [55]. Most of results stipulate that base pairs, double helix
grooves and strand breaks in DNAs can be primary binding sites
for topoisomerases inhibiting drugs [39]. As IN, similarly to
topoisomerases, is also a DNA cutting and joining enzyme, we
decided to investigate the binding of its best known inhibitor,
RAL, to DNA. To this end, we used UV absorbance, CD,
fluorescence and molecular dynamics with oligonucleotides to
assess the binding of the drug to viral DNA LTR ends with respect
to its INSTI activity.
UV-absorbance measurements
The first evidence of an interaction of RAL with the terminal
part of viral DNA either unprocessed or processed is provided by
UV-absorption titrations (Fig. 2 and Fig. S1 A and B). UV spectra
of selected oligonucleotides, LTR34, LTR32 and LTR30 (Fig. 1
A), between 200 and 380 nm, display a main signal centred at
about 260 nm and an additional peak around 200 nm, charac-
teristics of B-DNA (Fig. S1 A). The UV spectrum of RAL (Fig. 1 B)
between 200 nm and 380 nm consists in two peaks at 210 nm and
313 nm and a shoulder at 245 nm (Fig. S1 A), corresponding to
the contributions of the aromatic chromophores making up the
molecule. Fig. 2, shows the variations of the RAL spectrum
resulting from addition of 20 mM LTR32, LTR34 and LTR30 to
20 mM RAL (stoichiometry 1:1) after subtracting the spectrum of
free DNA at the same concentration. Completely different effects
are observed. With addition of LTR32 there is an emergence of a
signal at about 260 nm, exactly where the DNA contributes,
consistent with a change of conformation in LTR32 in response to
drug-DNA complex formation (Fig. S1 B). The increase of
intensity of the band at <205–210 nm, could arise from changes
in the contributions of both RAL and DNA, due to their
interaction. In contrast, the broad signal of RAL centred at
313 nm did not manifest any change, suggesting that the RAL
chromophore generating this signal remains free of interactions in
the complex. Noteworthy, addition of unprocessed LTR34 to
RAL produces the same effects as shown by LTR32, but, however,
less intense, while addition of blunt ended LTR30 is without
effects. Taken together the UV-absorption results shows that RAL
binds to the terminal part of LTRs, with a preference for the 39
processed DNA that carries the 59A
21C
2239dinucleotide over-
hang. In unprocessed LTR34 the 59A
21C
2239 dinucleotide is
involved in a duplex with the undeleted 59 G
2T
139 dinucleotide,
but this does not constitute a rigid barrier to the binding of RAL.
This can be explained by the important end fraying in
unprocessed LTR [35,36] that facilitates the RAL accommodation
into the terminal base pairs. The inability of RAL to bind the blunt
ended oligonucleotide LTR30, which is further devoid of both IN
binding and ST activities [34], confirms the functional importance
of the terminal 59A
21C
2239 step within either the unprocessed or
the processed viral DNA, regarding the capture of ligands.
CD spectroscopy measurements
The CD technique is widely used to determine the secondary
structures of proteins and nucleic acids and to follow the
conformational changes induced by their mutual association or
their binding to any type of ligand [56,57]. Here, CD was applied
to study the binding of RAL to LTR34 and LTR32, which mimic
the unprocessed and processed viral U5 DNA ends, respectively
Raltegravir Binding to Viral DNA
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show two main signals (negative at <250 nm and positive at
<280 nm) characteristics of B-DNA. In titration experiments,
RAL was added (concentrations from 10 mMt o8 0 mm) to
oligonucleotides maintained at 10 mM concentration. The spectra
recorded at drug: DNA ratios of 1, 2, 4, 6 and 8 showed a gradual
variation of intensity of the two B-DNA signals at <250 nm and
<280 nm. Similarly to UV-absorption experiments, effects were
larger with LTR32 than LTR34. However, the signals were not
shifted and no new signal induced by drug chromophores buried
in a chiral environment was detected. The CD changes were
assigned to a rearrangement of the nucleotide bases at the RAL
binding site or contiguous to it [27,58]. We will subsequently
observe that it is a single RAL molecule that is inserted at the LTR
extremity, so that one cannot expect the generation of a large
signal.
Fluorescence measurements
The quantification of interactions stabilizing partner molecules
is essential to the understanding of the complex formation.
Fluorescence intensity and anisotropy measurements are well
suited to a quantitative analysis of complexes as long as one of the
binding partners is fluorescent. The fluorescence anisotropy gives
information on both the stoichiometry of the complex and the
binding constant: Kd=[L]6[R]/[LR] (Kd: dissociation constant;
L: ligand and R: receptor) [13,26,59,60]. The Kds provided by
fluorescence anisotropy are confirmed by fluorescence intensity
experiments, where the fluorescent ligand molecule is titrated with
increasing concentrations of oligonucleotides.
The equilibrium saturation curves of the four fluorescein labeled
oligonucleotides and increasing concentrations of RAL recorded
by fluorescent anisotropy are shown in Fig. 4 and 5. The results
reported in Fig. 4 confirm the above UV-absorbance and CD
experiments, which indicated that RAL was able to interact with
processed LTR32 and unprocessed LTR34, but fail to interact
with the 39 dangling ended LTR32-I and the blunt ended LTR30.
Kds determined at midpoints are of <6 nM for LTR32 and
<20 nM for LTR34. Rather similar values were obtained with the
fluorescence intensity approach, using the oligonucleotides to
titrate RAL (Fig. S2). The stoichiometry for the binding of RAL to
LTR32 was determined by titrations at three different DNA
concentrations (9 nM, 20 nM and 30 nM) (Fig. 5). The mono-
phasic curves reached a same plateau after a variation of
anisotropy of DA<0.015. The three Kd values were quite similar
and provided a mean value of <6 nM. Application of the
Bujalwski and Lohman procedure [40], showed that a single RAL
molecule was bound to LTR32 (1:1 stoichiometry), in agreement
with the crystal structure results [15]. Noteworthy, the experi-
mental Kd for the binding of RAL to intasome [61] is higher the
one found for LTR32 alone (19 nM vs 6 nM).
The above results have several implications. First, the fact that
RAL binds to LTR34, is consistent with an end fraying lowering
the energy barrier for RAL accommodation into the terminal
bases. In retroviral DNAs, the fraying of terminal base pairs seems
amplified by the small 59C
4A
3:39G
24T
23 duplex just before in the
sequence. This dinucleotide duplex, invariant in retroviral DNAs,
is considered as one of the less stacked and most malleable
dinucleotide [62,63]. It could contribute to increase the motions
and disruption of the connected base pairs [35,36,62,63], which
according to several authors facilitate the IN binding and the
scissile bond cleavage [35,36]. Present study shows further that the
end fraying in LTR may contributes to the capture of INSTIs, but
the latter has no significant impact on the cut of the scissile bond,
as INSTIs are generally weak 39-P inhibitors. Second, the ability of
RAL to bind both LTR32 and LTR34 and its inability to bind
both the blunt ended LTR30 and the 39 dangling ended LTR32-I,
Figure 2. UV-absorption analysis of oligonucleotides. Spectra of
RAL 20 mM (black) together with 20 mM LTR32 (green), 20 mM LTR34
(blue), 20 mM LTR30 (red), in phosphate buffer pH 6, I=0.05, and MgCl2
5 mM final concentration.
doi:10.1371/journal.pone.0040223.g002
Figure 3. Circular dichroism analysis of oligonucleotides-drug
complexes. Spectra of LTR34 (A) and LTR32 (B) at 10 mM (black) and
difference spectra [LTR32/34 (10 mM)+RAL (10 mM, red; 20 mM, green;
40 mM, blue; 60 mM, orange; and 80 mM, purple)2LTR32/34 (10 mM)], in
phosphate buffer pH 6, I=0.05, and MgCl2 5 mM final concentration.
doi:10.1371/journal.pone.0040223.g003
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21C
2239 dinucleotide is required for
the drug-DNA complex formation, either as a dinucleotide
overhang at the end of processed LTR or as a dinucleotide within
a duplex subject to a large fraying at the end of unprocessed LTR.
Actually, a fair amount of data has been reported on the stabilizing
role of the 59A
21C
2239 overhang in the complex of IN with LTR
[34,64]. Here, we understand that the overhang can be also
involved in the LTR-RAL complex stability.
Molecular modelling
Our UV-absorption, CD and fluorescence experiments provide
insight on the binding of RAL to the processed (LTR32) and
unprocessed (LTR34) DNAs. However, they do not give
information on the binding events and the type of interactions
stabilizing molecular complexes. On the other hand, MD
simulations can provide atomic details on structural and dynamic
events governing the complex formation, while MMPBSA
provides the binding free energies and allows the quantification
of the complex stability [30,51,65]. We performed MD simulations
(400 ns in total) and MMPBSA calculations in order to unravel the
role of viral DNA ends as possible primary targets in the
mechanism of IN inhibition by RAL. Indeed, MMPBSA
overestimate the binding values, which is not surprising since this
method is known for this defect [51,66]. However, the MMPBSA
values presented hereafter provide the same ranking as that given
by fluorescence, in showing that the complexes of RAL with
processed LTR are more stable than those with unprocessed LTR.
Equilibration of the MD simulations
We applied MD simulations to the analysis of RAL complexes
with LTR34 and LTR32 ends. MD trajectories monitored by the
root-mean-square displacement (RMSD) values of heavy atoms
with respect to the X-ray structure (PDB code: 3OYA) are shown
in Fig. 6A and B. Similar RMSD values were obtained when the
sugar C49 atoms (green curve in Figure 6A for LTR34) or the
phosphorus atoms (not shown) were monitored. The trajectories
show that the system is stabilized after 2 ns and conserves the same
RMSD value till the end of the simulation (100 ns) for both
LTR34 and LTR32. A duplicate simulation also of 100 ns gives
similar results. LTR34 displays higher RMSD values than LTR32
(the purple curve in Fig. 6A is very similar to the black and the
blue in Fig. 6B). The important fraying (base pair disruption or
impairing) of the two terminal base pairs of LTR34, is the main
reason of the greater flexibility of LTR34 in comparison with
LTR32. This is particularly obvious in the root-mean-square
fluctuation (RMSF) of the sugar C49 atoms (see Fig. 6C and D).
RAL binding to DNA
Each oligonucleotide yields two complexes: RAL-LTR34-1,
RAL-LTR34-2 and RAL-LTR32-1, RAL-LTR32-2 (Fig. 7).
Table 1 summarizes the free energy values for the binding of
RAL to the LTR34 and LTR32 ends, calculated with the
MMPBSA method. Values agree with a favorable binding of RAL
to both unprocessed LTR34 (RAL-LTR34-1, RAL-LTR34-2) and
processed LTR32 (RAL-LTR32-1, RAL-LTR32-2). The binding
energy characterizing RAL-LTR34-1 is less favorable compared
with RAL-LTR34-2, and also compared with the two other
complexes, RAL-LTR32-1and LTR32-2. Compared with RAL-
LTR34-2 (and the other two complexes), RAL-LTR34-1 displays
a very distinct binding mode of RAL. In fact, it is the only case
where the drug uses its oxadiazole moiety to bind DNA. The ring
intercalates in between the terminal base pairs, while the
remaining of the molecule is solvent exposed. In RAL-LTR34-2,
RAL uses its fluorobenzyl moiety to interact with the G
24 and the
T
23 bases, and its pyrimidine ring to interact with the A
3 of the
conserved C
4pA
3step. Interactions of the fluorobenzyl moiety with
of G
24 and T
23 bases are also found in both RAL-LTR32-1 and
RAL-LTR32-2. In RAL-LTR32-1 the fluorobenzyl group inter-
acts with the C
4 base, while in RAL-LTR32-2 the pyrimidine ring
interacts with the A
3 base.
It is worth noting, that the terminal adenine A
3 bearing the
recessed 39-hydroxyl, samples two different conformations in the
calculated RAL-LTR32 complexes. These two conformations are
found in the crystal structures of RAL bound to the PFV intasome
(PDB codes: 3L2T [15] and 3OYA [18]). In the corresponding
Fig. 8, the role of the fluorobenzyl ring containing moiety appears
essential to stabilization of the RAL-DNA complex and conse-
quently to induction of inhibition. In three complexes out of four
provided by calculations, the ring partakes in key interactions.
Actually, the stacking of the aromatic ring on the cytosine C
4 base
and the interactions of the RAL amide group with the adenine A
3
Figure 4. Quantitative analysis of RAL binding to oligonucle-
otides. Fluorescence anisotropy titration of the four oligonucleotides
LTR32 (black), LTR34 (red), LTR32-I (blue) and LTR30 (green) at 20 nM by
increasing concentrations of RAL (from 10
212 Mt o1 0
24 M). Kds
obtained from titrations of LTR32 and LTR34 at 20 nM are indicated
near the corresponding curves.
doi:10.1371/journal.pone.0040223.g004
Figure 5. Thermodynamic parameters for the binding of RAL to
LTR32. Titration of LTR32, at three different concentrations: 9 nM
(black), 20 nM (red), and 30 nM (blue). Curve treatment provided a 1:1
stoichiometry for the complex formation and an average Kd of <6n M
for the binding affinity. Samples were in phosphate buffer pH 6, I=0.05,
at 5uC, MgCl2 5 mM final concentration.
doi:10.1371/journal.pone.0040223.g005
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4A
339step, as well as the interaction of
the fluorine atom with the guanine G
24 at the back of the cavity,
are all found in the crystal structures of INSTI-intasome [18].
Moreover, the fluorobenzyl moiety in RAL-LTR34-2 displays the
same stabilizing interactions than in RAL-LTR32-1, or 2, and in
the crystal structures of RAL-intasome [15].
Figure 6. MD simulations of the RAL-LTR34 and RAL-LTR32 complex systems (PFV oligonucleotides), using GROMACS with the
AMBER force field. (A) Time evolution of RMSD (root mean square deviation) values based on all the heavy atoms for the two LTR34 trajectories
(black: LTR34-1 and blue: LTR34-2). RMSD calculations for a single trajectory were also performed using the sugar C49 atoms (green: LTR34-1) and
repeated for LTR34 devoid of 39-AT (purple). (B) Time evolution of RMSD values of LTR32 for two trajectories (black: LTR32-1 and blue: LTR32-2). (C)
RMSF (root mean square fluctuation) variations of sugar C49 atoms for LTR34 and (D) RMSF variations of sugar C49 atoms for LTR32.
doi:10.1371/journal.pone.0040223.g006
Figure 7. Snapshots from the two 100 ns trajectories of RAL in complex with unprocessed LTR (LTR34-1 and 2, top) and processed
LTR (LTR32-1 and 2, bottom). RAL is colored in slime green and bases in sandy brown, except for atoms at interacting distances which are colored
using the usual code (hydrogen in white; nitrogen in blue; and oxygen in red) except for carbons, while the Mg
2+ ion is represented by magenta ball.
Selected snapshots are 0 ns (the initial structure), 50 ns and 100 ns.
doi:10.1371/journal.pone.0040223.g007
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The calculated binding energies are shown in table 1. We note
that when the fluorobenzyl moiety is not involved in interactions
(RAL-LTR34-1), the binding energy is the highest, which confirms
the key role of the halogenated moiety in the complex
stabilization. In the four RAL-DNA complexes, the van der
Waals (VDW) interactions (Evdw) are predominating which is a
relatively common feature in complexes of organic ligands with
nucleic acids [67]. In the two complexes of RAL with unprocessed
LTR34, the fluorobenzyl ring has much more favorable VDW
interactions compared with the oxadiazole group: ([LTR34-
2]vdw2[LTR34-1]vdw=218 kcal/mol). The solvent
(DGPB+DGSASA) also contributes to a favorable binding, while
both the electrostatics and the entropy are not favorable to the
binding. The latter affects apparently equally the binding of RAL
to LTR34 and to LTR32. Since the electrostatics and the solvation
forces neutralize each other, the VDW interactions become the
main binding contribution. Finally, the binding of RAL to viral
DNA ends appears as an enthalpy driven process, rather than an
entropy driven one.
Binding free energies: comparisons of simulated with
experimental structures
The free energy, DG, values for the binding of RAL to LTR34
and LTR32, provided by the MMPBSA methodology are
overestimated compared with the experimental DG values
determined by fluorescence anisotropy (DGLTR32<210.5 Kcal/
mol and DGLTR34<29.8 Kcal/mol). This result is not unexpected
as MMPBSA is known for this defect, especially when a non-
polarizable force field is used. Yet, the fluorescence titration
experiments and the molecular dynamics approaches lead to
similar conclusions. Both show that RAL can form stable
complexes with LTR34 and LTR32. The MMPBSA calculations
predict a binding of RAL to viral DNA which is enthalpy driven
and assign an important role to the VDW forces in the complex
stabilization. The finding of an enthalpy driven binding is not so
surprising, as RAL, similarly to intercalators, also used p-p
stackings to interact with the bases of DNA (Fig. 7). A dataset
consisting of 26 binding interactions has shown that intercalating
molecules bind to DNA with a favorable enthalpy contribution
[68], while the binding of groove-binders is due more to a
favorable entropy [68]. Actually, the binding of RAL to LTRs is
characterized by a mean DH/DG ratio of about 1.50, while a DH/
DG ratio ranging from 0.83 to 1.97 is considered as a clear
signature of enthalpy driven binding [68]. Although RAL has a
structure reminiscent of some intercalators, our hydrodynamic
studies (not shown) indicate that it is unable to insert into base
pairs of the DNA double helix. Indeed, the anchoring of RAL at
the end of unprocessed LTR needs of the end fraying. In processed
LTR the room opened at the DNA end by the release of the
59G
2T
139 (59A
2T
139 for IN-PFV) dinucleotide facilitates the RAL
interaction. In both processed and unprocessed LTRs we find that
the 59A
21C
2239 (59A
21T
2239 for PFV IN) dinucleotide partakes
in the DNA-drug complex stabilization. Yet, in the crystal
structure of the ternary complex of RAL with the PFV intasome,
Table 1. Calculated binding parameters for the complexes of RAL with LTR32 and LTR34.
Complex D Eele D EVDW D EMM D GPB D GSASA D HT DS D G
LTR34-1 258.9617.0 230.364.0 228.6615.0 2256.1615.0 22.460.2 229.963.7 218.7 211.263.7
LTR34-2 253.0613.0 248.564.0 204.5612.5 2249.2612.7 23.360.2 248.065.0 216.6 231.465.0
LTR32-1 194.3619.7 236.863.5 157.5618.9 2200.8618.5 23.060.1 246.364.0 215.1 231.264.0
LTR32-2 166.6611.0 235.064.0 131.6610.7 2171.5610.3 23.160.2 243.065.3 217.5 225.565.3
The free energy DGMMPBSA from two trajectories for each system (LTR34-1, 2 and LTR32-1, 2) and averaged over 500 frames from each trajectory. Energies and standard
deviations are given in kcal/mol. Eele: Coulombic energy; Evdw: van der Waals energy; EMM: total molecular mechanics energy (Eele+Evdw); GPB: polar solvation free energy
based on Poisson-Boltzmann; GSASA: Non-polar solvations free energy based on SASA; TDS: the entropy contribution to the binding calculated by the QH; DG: the total
free energy.
doi:10.1371/journal.pone.0040223.t001
Figure 8. Details of the interactions of RAL with its surrounding
amino acids and nucleotides as observed in the two X-ray
structures of RAL bound to the PFV intasome (pdb codes: 3L2T
and 3OYA). RAL is shown in slime green and IN and LTR residues in
sandy brown. The amino acids and nucleotides giving interactions are
shown in sticks with hydrogens in white, nitrogens in blue and oxygens
in red. Mg
2+ ions are represented by light green balls. The main
difference between 3L2T and 3OYA structures concerns the orientation
of the adenine A3.
doi:10.1371/journal.pone.0040223.g008
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was already the case in the intasome [15]. Here, either the
interactions of the 59A
21T
2239 overhang could be stronger with
the protein than with RAL, and be prioritized, or the crystal
packing could prevent RAL from reaching its target. Noteworthy,
RAL makes van der Waals contacts with both the invariant
59C
4pA
339step known for its functional importance at the LTR
end [34,61] and the guanine G
24 facing the cytosine C
4 of this
step. These interactions are also found in calculated and crystal
structures of DTG, a structural analogue showing activity against
RAL-resistant mutants [69]. In that case it has been suggested that
DNA could make the greatest energetic contribution to DTG
binding.
The particular properties of LTR ends contribute to the
molecular fitting of RAL to DNA prior 39-P. Owing to the high
flexibility prevailing at the unprocessed DNA end the energy loss
during complex formation is weak. This is especially true with
regard to the drug intercalation which is an entropy costly
mechanism requiring both base pair destacking and DNA
distortion to create a suited site for the binding, and resulting in
a damping of motions and stiffening of the duplex.
Conclusion
Our experimental and theoretical studies underline the partic-
ular role of the LTR terminal nucleotides in the binding of RAL to
viral DNA. In previous reports, the antiviral drug RAL has been
described as an INSTI acting at the interface of DNA-enzyme
according to an important lattice of interactions with the processed
LTR end, two metal ions and IN [3,15,18]. The recently
published X-ray crystallography results describing the binding of
INSTIs to the PFV-intasome, have confirmed most of the previous
biochemical observations, including the two metal binding, and
provided outstanding information on the inhibition mechanism
used by inhibitors [15,17,18]. Yet, so far reported studies had not
addressed the possible binding of IN inhibitors to the viral DNA
end, especially prior to 39-P. Actually, like other small organic
molecules with chemotherapeutic activities, RAL binds directly
and selectively to DNA. However, in contrast to the anticancer
agents, as for example anthracyclines and ellipticines, RAL
occupies selective binding sites on DNA. Its binding to the
unprocessed LTR end could be at the basis of the observed 39-P
inhibition. What appears is that the capture of the drug by
unprocessed LTR entails a small damping of motions (fraying) in
the terminal base pairs (Fig. 9). Initial studies [35,36,70–73] have
shown that any restriction of fraying in the terminal base pairs by
either extension of the duplex [35,71] or chemical linkage of the
duplex ends [73] impairs the 39-P reaction. Remarkably, RAL
keeps the same conformation within the complex with unprocessed
and processed DNAs, with its halogenated ring in face to face
contact with the cytosine base of the conserved 59C
4pA
339 step,
and the adenine A
3 bearing the recessed 39-hydroxyl group moved
from its operative position.
At the end our work could help to better understand some of the
factors contributing to the mechanism of action of IN inhibitors.
Above all, we have shown that RAL binds to the LTR end prior
39-P reaction, but the impact on this reaction is small. The fact
that the contacts established by RAL with the processed LTR end
mainly concern the nucleotides C
4,A
3 and G
24, pushes us to
speculate that new drugs giving an increased number of
interactions with these highly conserved bases, at expense of
interactions with amino acid side chains of the protein active site,
will be better INSTIs and weaker resistance inducers.
Supporting Information
Figure S1 UV-absorption analysis of oligonucleotides
and raltegravir free and in complexes. (A) Spectra of RAL
(80 mM, in red) and LTR32 (10 mM, in black) in phosphate buffer
pH 6, I=0.05, MgCl2 5 mM final concentration. (B) Spectra of
RAL 20 mM, (black), in complex with LTR32 (1 mM, red), LTR32
(5 mM, blue) and LTR32 (10 mM, green).
(TIF)
Figure S2 Binding of oligonucleotides to raltegravir.
Titration data for LTR32 (black) and LTR34 (red) and
corresponding Kds are obtained from fluorescence intensity in
so called reverse experiments. The spectra of raltegravir recorded
at different LTR34 concentrations are given in insert.
(TIF)
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